JA
Jason Aryeh (Director) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in Ligand Pharmaceuticals Incorporated (LGND). The largest single filing was $1.2M of LGND (5,000 sh across 2 lots, as filed), executed Jun 10. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
2
0 buys · 2 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$1.9M
shares × price, as filed
Last traded
Nov 2
Filed Nov 3
Median ADV $104.4M across their filed names
Open performance→Volume by month
Buys $0
Sells $3.6M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
LGNDRecent filings
LGNDSALE
Ligand Pharmaceuticals Incorporated
View filing →
$612K1,909 sh across 2 lots
Exec Oct 30
Filed Nov 3 · 7:39 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated View filing → $1.2M
5,000 sh across 2 lots
Exec Jun 10
Filed Jun 12 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated View filing → $1.7M
10,000 sh across 3 lots
Exec Sep 23 2025
Filed Sep 24 2025 · 5:30 PM ET